Unknown

Dataset Information

0

Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic.


ABSTRACT:

Background

Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long-term sequelae is a priority. Intensive inpatient chemotherapy (e.g., carboPEI = carboplatin/etoposide/ifosfamide) has been effectively employed to reduce radiotherapy treatment volume/dose. Outpatient-based carboplatin monotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathology), and successful vinblastine monotherapy induction (with 77% tumor volume reduction after just two weekly vinblastine doses) has recently been reported in an intracranial germinoma patient.

Methods

Adapted UK guidelines for germ cell tumor management were distributed during the COVID-19 pandemic, including nonstandard treatment options to reduce hospital visits and/or admissions. This included vinblastine monotherapy for intracranial germinoma (6 mg/m2 intravenously, or 4 mg/m2 for moderate count suppression, delivered weekly). We describe two such patients treated using this approach.

Results

A 30-year-old male with a localized pineal tumor received 12-week vinblastine induction, with >60% volume reduction, prior to definitive radiotherapy. A 12-year-old female with a metastatic suprasellar tumor and progression at all sites of disease whilst awaiting proton radiotherapy received two vinblastine doses with good early response, including 36% primary tumor volume reduction. The patients tolerated vinblastine well.

Conclusion

Patients with intracranial germinoma have excellent outcomes, and reduction of late effects remains a priority. The description of vinblastine monotherapy in these intracranial germinoma patients warrants further exploration.

SUBMITTER: Murray MJ 

PROVIDER: S-EPMC8662027 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-BSST1055 | biostudies-other
| 2346925 | ecrin-mdr-crc
| S-EPMC7723459 | biostudies-literature
| S-EPMC6382366 | biostudies-literature
| S-EPMC8373584 | biostudies-literature
| 2656898 | ecrin-mdr-crc
| S-EPMC7530817 | biostudies-literature
| S-EPMC8216850 | biostudies-literature
| S-EPMC9673210 | biostudies-literature
| S-EPMC8612769 | biostudies-literature